AXIM BIOTECHNOLOGIES, INC. (AXIM)
2024-06-30 | ||||
|---|---|---|---|---|
| Revenues | 17,479 | |||
| Cost of goods sold | 1,744 | |||
| [gross profit] | 15,735 | |||
| Selling, general and administrative | 472,984 | |||
| Research and development expenses | 4,063 | |||
| Depreciation and amortization | 108,129 | |||
| [operating expenses] | 585,176 | |||
| [operating income (loss)] | -569,441 | |||
| [other nonoperating income (expense)] | 1,700,374 | |||
| [income (loss) from continuing operations before income taxes, noncontrolling interest] | -2,269,815 | |||
| Net loss | -2,269,815 | |||
| Net loss | -2,269,815 | |||
| [net loss] | -2,269,815 | |||
| Basic eps | -0.01 | |||
| Diluted eps | -0.01 | |||